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services and policy research to inform rural health practitioners, managers, and policy makers in Kentucky.    
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Background on Opioid Use and Buprenorphine 
 
According to the Centers for Disease Control and Prevention (CDC), drug overdose deaths involving 
opioids have more than quadrupled in the past 15 years, driven by increases in both prescription and 
illicit opioid abuse.1  The state of Kentucky is no exception to the growing prevalence of opioid abuse.  
Since 2000, Kentucky resident drug overdose deaths by prescription opioids and heroin have steadily 
increased, and from 1999 to 2008 admissions to substance abuse treatment programs for opioid 
addiction increased by 900%.2,3  Rates of hospitalizations and deaths due to opioid abuse are highest in 
rural counties, particularly those in eastern Kentucky.2,4 
 
In 2000, the United States Congress approved the Drug Addiction Treatment Act (DATA) to provide 
physicians more independence to prescribe buprenorphine to treat opioid addiction.5  Buprenorphine is 
an opioid partial agonist that diminishes dependency to opioids, has lower potential for misuse than 
methadone, and is much safer in the case of drug overdose.5   Buprenorphine can be prescribed in a 
variety of medical settings and treatment is administered in 3 phases.5  The induction phase is within 12 
to 24 hours of the patient refraining from opioid use and is monitored in the physician’s practice setting.5 
Next is the stabilization phase in which the patient’s withdrawal symptoms are minimal.5  During this 
phase, buprenorphine doses can be adjusted or taken on an alternating schedule.5 The maintenance 
phase is then used to standardize dosage and set a personal schedule for treatment completion.5  After 
completing an 8-hour online training through the Substance Abuse and Mental Health Services 
Administration (SAMHSA) and approval by the DEA, physicians are able to treat up to 30 patients within 
the first year of certification or up to 100 patients thereafter.5  A recent federal regulation raised the limit 
to 275 patients among physicians who already had a 100-patient waiver and had a history of prescribing 
buprenorphine to 100 patients for a minimum of 1 year.6 
 
As of February 2015, only 2.2% of U.S. physicians possessed a waiver to prescribe buprenorphine.7  A 
national survey found that physicians often do not maximize their waiver limit, with an average of 39 
patients being treated by a physician with a 100-patient waiver.8  In terms of distribution, 53.4% of U.S. 
counties are without a waivered physician, leaving approximately 30 million Americans with potentially 
limited access to buprenorphine treatment.7  Additionally, waivered physicians are predominant in the 
specialties of psychiatry and primary care at 41.6% and 36.7%, respectively.7  In a separate study in the 
state of Washington, it was found that primary care physicians represent the plurality of waivered 
physicians in urban areas and the majority of waivered physicians in rural counties. Also, almost all 
specialists were located in urban counties.9   
 
 
Purpose of the Report 
Drug overdose and substance use treatment admissions data indicate that opioid use is problematic in 
Kentucky, but little information exists about the geographic availability of buprenorphine treatment 
across the state.  Furthermore, there is even less information about the characteristics of the physicians 
prescribing buprenorphine.  This report describes the availability of buprenorphine treatment in 
Kentucky. 
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Methods 
 
Information on DATA-Waivered Physicians 
We obtained the name, type of medical degree, and practice telephone number and address for each 
DATA-waivered physician from the Substance Abuse and Mental Health Services Administration 
(SAMHSA) publicly available buprenorphine treatment physician locator database. 
Of the 643 waivered physicians in the state of Kentucky as of October 2015, 424 (65.9%) were publicly 
listed in the SAMHSA database (located at www.samhsa.gov/medication-assisted-treatment/physician-
program-data/treatment-physician-locator). 
 
We obtained additional information about these physicians, including their age, gender, specialty, and 
additional locations of practice, from the publicly available Healthgrades website (located at 
www.healthgrades.com).  Using these 2 data sources, we categorized physician practices into primary 
care or specialty care categories.  The specialty category was further divided into 7 subgroups for 
selected analyses. 
 
Availability by Metropolitan, Micropolitan, and Other Non-Metropolitan Areas 
To determine the availability of buprenorphine treatment in all 120 Kentucky counties, each physician’s 
city was matched to a corresponding county.  Counties were categorized as metropolitan, micropolitan, 
or other non-metropolitan according to U.S. Office of Management and Budget definitions as shown in 
Figure 1.10  Metropolitan counties include an urban core of at least 50,000 persons.  Micropolitan counties 
are those with a population of at least 10,000 but fewer than 50,000, and other non-metropolitan rural 
counties are those with a population of fewer than 10,000 persons.  Of the 120 counties in Kentucky, 35 
are designated as metropolitan, 27 as micropolitan, and 58 as other. 
 
Figure 1.  Metropolitan, Micropolitan, and Other Non-Metro Counties in Kentucky 
 
 
Analysis 
We calculated the number of DATA-waivered physicians per 10,000 persons residing in each of 
Kentucky’s 120 counties.  We then compared the mean number of waivered physicians per 10,000 
persons and the percentage of counties with at least one waivered physician across metropolitan, 
micropolitan, and other non-metropolitan status.  Lastly, we compared the specialty composition across 
metropolitan, micropolitan, and other non-metropolitan areas. 
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Results 
 
 
Waivered Physicians by Metro/Micro/Other Non-Metro Areas 
 
As shown in Figure 2, 57% of metropolitan, 70% of micropolitan, and 45% of other non-metropolitan 
counties had 1 or more waivered physicians in 2015. 
 
Figure 2.  Percentage of Counties with a DATA-Waivered Physician 
 
 
Moreover, as shown in Figure 3, micropolitan counties had the highest mean number of waivered 
physicians per 10,000 persons (1.03), followed by means of 0.60 and 0.79 waivered physicians per 
10,000 persons in metropolitan and other non-metropolitan counties, respectively.   
 
Figure 3.  Mean # of Waivered Physicians by Metro/Micro/Other Status 
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Waivered Physicians by Specialty 
As shown in Table 1, 41.3% of waivered physicians were primary care physicians; the remaining 58.7% 
were other specialists.  Psychiatry represented 23.3% of all waivered physicians in Kentucky in 2015. 
 
Table 1.  Number and % of Waivered Physicians by Primary Specialty 
Total = 424, % Specialty, # in specialty Category # (%) in specialty  
Primary Care, n=175 
(41.3%) 
Family Medicine, 102 
General Practice, 2 
Geriatric Medicine, 1 
Hospital Medicine, 1 
Internal Medicine, 68 
Pediatrics, 1  
Primary Care 
 
175 (41.3%) 
Specialty Care, n=249 
(58.7%) 
Addiction Psychiatry, 5 
Adult Psychiatry, 1  
Child & Adolescent Psychiatry, 13 
Clinical Psychiatry, 1 
Forensic Psychiatry, 3 
General Psychiatry, 1 
Psychiatry, 75  
Psychiatry 99 (23.3%) 
 Obstetrics & Gynecology, 18 
Reproductive Endocrinology & Infertility, 1 
Maternal-Fetal Medicine, 3 
Neonatal/Perinatology, 1 
Reproductive 
Medicine 
23 (5.4%) 
 Diagnostic Radiology, 5 
Radiology, 2 
Nuclear Radiology, 1 
Vascular & Intervention Radiology, 1 
Radiology 9 (2.1%) 
 Anesthesiology, 35 
Pain Medicine, 5 
Pain 
Management 
40 (9.4%) 
 Critical Care Medicine, 2 
Emergency Medicine, 25 
Emergency 
Medicine 
27 (6.4%) 
 Bariatric Surgery, 1 
General Surgery, 7 
Orthopedic Surgery, 8 
Surgery 16 (3.8%) 
 Addiction Medicine, 4 
Anatomic & Clinical Pathology, 1 
Cardiology, 1 
Endocrinology, Diabetes & Metabolism, 1 
Infectious Disease Medicine, 1 
Nephrology, 3 
Neurology, 2 
Opthalmology, 1 
Osteopathic Manipulative Therapy, 4 
Physical Medicine & Rehabilitation, 5 
Preventive Medicine, 2 
Psychosomatic Medicine, 1 
Pulmonology, 1 
Radiation Oncology, 1 
Rheumatology, 2 
Sleep Medicine, 1 
Sports Medicine, 1 
Urology, 3 
Other 35 (8.3%) 
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Waivered Physician Specialists by Metro/Micro/Other Rural Areas 
Table 2 describes the distribution of specialists among metropolitan, micropolitan, and other non-
metropolitan counties.  In other non-metro counties, 71.95% of waivered physicians were primary care 
physicians, compared to 45.78% and 30.12% in micropolitan and metropolitan counties, respectively.  In 
other words, the majority of waivered physicians in metropolitan and micropolitan counties were 
specialists, with 29.73% of waivered physicians in metropolitan counties being psychiatrists.  
 
Table 2.  Waivered Physician Specialists by Metro/Micro/Other Non-Metro Status 
Specialty Metropolitan 
n=259, (61.1%) 
Micropolitan 
n=83, (19.6%) 
Other 
n=82, (19.3%) 
Total 
n=424, (100%) 
Primary Care 78 (30.12%) 38 (45.78%) 59 (71.95%) 175 (41.3%) 
Psychiatry 77 (29.73%) 16 (19.28%) 6 (7.32%) 99 (23.3%) 
Reproductive 
Medicine 
14 (5.41%) 4 (4.82%) 5 (6.10%) 23 (5.4%) 
Radiology 7 (2.70%) 2 (2.41%) 0 (0%) 9 (2.1%) 
Pain Management 33 (12.74%) 6 (7.23%) 1 (1.22%) 40 (9.4%) 
Emergency Medicine 18 (6.95%) 6 (7.23%) 3 (3.66%) 27 (6.4%) 
Surgery 10 (3.86%) 2 (2.41%) 4 (4.88%) 16 (3.8%) 
Other 22 (8.49%) 9 (10.84%) 4 (4.88%) 35 (8.3%) 
 
 
Conclusion   
 
Nearly half (46%) of Kentucky’s counties do not have a waivered physician; approximately 1 million 
Kentuckians, or a quarter of the population, are without immediate access to buprenorphine.  Moreover, 
potential access to buprenorphine is not well-distributed across metropolitan, micropolitan, and other 
non-metropolitan areas within the state. 
 
Nationally, 41.6% of waivered physicians are psychiatrists.7  However, only 23.3% of waivered 
physicians in Kentucky are psychiatrists and 77.8% of those practice in metropolitan counties.  Thus, 
many micropolitan and other non-metropolitan residents may face greater barriers to buprenorphine 
treatment from psychiatrists, which are arguably the best-trained physician group for diagnosing and 
treating substance abuse.  
 
Because SAMHSA allows physicians the option to publicly post their information on the SAMHSA 
database, we only had access to information for approximately two-thirds of waivered physicians.  Thus, 
we likely underestimated the average number of waivered physicians.  Additional research is warranted 
to further investigate the availability of and demand for buprenorphine in Kentucky. 
 
In conclusion, several steps could be taken to improve the availability of buprenorphine treatment across 
Kentucky.  Physicians who have a waiver should be encouraged to maximize the number of patients they 
may treat.  Currently non-waivered physicians practicing in areas with high rates of opioid abuse may 
need additional training on how to provide buprenorphine and associated counseling services.   
 
Institute for Rural Health Policy Report :   Availability of Buprenorphine Treatment   
7     
 
References 
1. Centers for Disease Control and Prevention. (2016, March 14). Opioid Data Analysis. Retrieved 
April 4, 2016, from http://www.cdc.gov/drugoverdose/data/analysis.html 
 
2. Slavova, S., Bunn, T. L., & Gao, W. (2015). Drug Overdose Deaths in Kentucky, 2000 - 2013. 
Kentucky Injury Prevention and Research Center, 2-17. Retrieved November, 2015, from 
http://www.mc.uky.edu/kiprc/projects/ddmarpdak/pdf/KyDrugOverdoseDeaths-2000-2013.pdf 
 
3. Smith, C., Cambron, S., Baker, A., Centers, I., Clayton, R., Crouch, R., & Wilson, R. (2011). 
Prescription Drug Trends in Kentucky Short Report. Kentucky State Epidemiological Outcomes 
Workgroup, 2-9. Retrieved November, 2015, from http://chfs.ky.gov/NR/rdonlyres/87074E8C-
69F5-426D-A3E2-5BA341F7252A/0/PrescriptionDrugTrendsinKentuckyShortReport.pdf 
 
4. Akers, D., Slavova, S., & Bunn, T. L. (2016). Drug Overdose Inpatient Hospitalizations in Kentucky, 
2000 - 2014. Kentucky Injury Prevention and Research Center, 2-22. Retrieved February, 2016, 
from http://www.mc.uky.edu/kiprc/programs/kdopp/Drug-Overdose-Hospitalizations-2000-
2014.pdf 
 
5. Substance Abuse and Mental Health Services Administration. (2015, September 25). 
Buprenorphine. Retrieved October 9, 2015, from http://www.samhsa.gov/medication-assisted-
treatment/treatment/buprenorphine 
 
6. Substance Abuse and Mental Health Services Administration. (2015, September 25). 
Buprenorphine. Retrieved October 9, 2015, from 
http://www.samhsa.gov/medication-assisted-treatment/buprenorphine-waiver-
management/increase-patient-limits 
 
7. Rosenblatt, R. A., Andrilla, C. A., Catlin, M., & Larson, E. H. (2015). Geographic and Specialty 
Distribution of US Physicians Trained to Treat Opioid Use Disorder. Annals of Family Medicine, 
13(1), 23-26. 
 
8. Arfken, C. L., Johanson, C. E., Di Menza, S., & Schuster, C. R. (2010). Expanding treatment capacity 
for opioid dependence with office-based treatment with buprenorphine: National surveys of 
physicians. Journal of Substance Abuse Treatment, 39, 96-104. 
 
9. Kvamme, E., Catlin, M., Banta-Green, C., Roll, J., & Rosenblatt, R. (2013). Who prescribes 
buprenorphine for rural patients? The impact of specialty, location and practice type in 
Washington State. Journal of Substance Abuse Treatment, 44, 355-360. 
 
10. Nussle, J. (2008). OMB Bulletin No. 09-01 (pp. 1-148) (United States of America, Executive Office of 
the President, Office of Management and Budget). Washington, D.C. Retrieved April 10, 2016, from 
https://www.whitehouse.gov/sites/default/files/omb/assets/omb/bulletins/fy2009/09-01.pdf 
 
 
